Company Profile
Chronix Biomedical technology detects trace amounts of unique DNA sequences in the blood that are associated not only with specific cancers but also patient specific. Chronix Biomedical is now creating blood tests that can be used routinely to detect and identify the start of early stage cancer process and the dynamic changes within the disease process that impact treatment, such as disease recurrence or response to medication.
CREATING ROUTINE LABORATORY TESTS FOR CANCER WHERE NONE EXIST
This technology will enable Chronix Biomedical to develop dozens of new cancer tests based on the company’s pioneering breakthrough approach to serum DNA analysis. Tests currently available on the market have weak sensitivity and specificity and therefore have limited clinical utility.
Disease-independent approach
Chronix is initially focusing on cancer, but its platform can be easily adapted for any disease. It is expected the platform will have very broad applications.
Click here to view our technology.
COMMERCIAL APPLICATIONS
Collaborators: USDA, University of Göttingen, International Myeloma Foundation, University of Calgary, South Dakota State University
Validated Science: Recent independent research and peer-reviewed publications: Clinical Chemistry, Blood, Nucleic Acids Research, Zoonoses and Public Health
Patents: Issued and filed intellectual property rights
Chronix Biomedical technology detects trace amounts of unique DNA sequences in the blood that are associated not only with specific cancers but also patient specific. Chronix Biomedical is now creating blood tests that can be used routinely to detect and identify the start of early stage cancer process and the dynamic changes within the disease process that impact treatment, such as disease recurrence or response to medication.
CREATING ROUTINE LABORATORY TESTS FOR CANCER WHERE NONE EXIST
“I see the future of excellent health care treatment as dependent on personalized medicine. Chronix’s technology, which identifies critical molecular diagnostic markers, will facilitate achievement of this goal.”
Paul E. Freiman,
Chairman, Board of Directors
Chronix utilizes its unique capabilities to determine the DNA signatures associated with specific cancers that can be used to identify persons with undiagnosed cancer, and to track changes in the cancer status during the course of treatment. Paul E. Freiman,
Chairman, Board of Directors
This technology will enable Chronix Biomedical to develop dozens of new cancer tests based on the company’s pioneering breakthrough approach to serum DNA analysis. Tests currently available on the market have weak sensitivity and specificity and therefore have limited clinical utility.
Disease-independent approach
Chronix is initially focusing on cancer, but its platform can be easily adapted for any disease. It is expected the platform will have very broad applications.
Click here to view our technology.
COMMERCIAL APPLICATIONS
- Blood Test for Breast Cancer – a blood test that will have the highest sensitivity and specificity.
- Blood Test for Prostate Cancer – a blood test that will have the highest sensitivity and specificity.
Collaborators: USDA, University of Göttingen, International Myeloma Foundation, University of Calgary, South Dakota State University
Validated Science: Recent independent research and peer-reviewed publications: Clinical Chemistry, Blood, Nucleic Acids Research, Zoonoses and Public Health
Patents: Issued and filed intellectual property rights
Phone: 408-960-2306 | Email: info@chronixbiomedical.com
Content copyright . Chronix Biomedical. All rights reserved.
